北京大学教育学院
GRADUATE SCHOOL OF EDUCATION, PEKING UNIVERSITY

Advanced Academic Writing
UCAS-M 2018

Class 6 – 19.04.2018

Example: Motivation



To investigate whether HFn possesses the ability of traversing the BBB, we performed a BBB transcytosis assay both in vitro and in vivo. In a BBB transcytosis assay using in vitro models constructed of either human or mouse BBB ECs (Figure 1A), we found that HFn effectively traversed both the mouse and human BBB (Figure 1B, C). In comparison, control human L-ferritin (LFn) failed to traverse the BBB. The rate of HFn transport across the BBB was between 5 to 6 times higher than that of LFn after one hour of incubation with ferritin proteins (Figure 1B, C). To evaluate whether our HFn nanocarriers are able to transcytose, we also employed a co-culture model consisting of mouse BBB ECs and pericytes. The rate of HFn transport across the co-culture BBB model was similar to the rate observed in the mono culture BBB model (Figure S1A, B). Importantly, we found that HFn nanocarriers maintain their intact structure after traversing the BBB (Figure S1C, D). Together, these results clearly demonstrated that HFn has the ability to traverse the BBB in vitro.

Example: Active Voice



To investigate whether HFn possesses the ability of traversing the BBB, we performed a BBB transcytosis assay both in vitro and in vivo. In a BBB transcytosis assay using in vitro models constructed of either human or mouse BBB ECs (Figure 1A), we found that HFn effectively traversed both the mouse and human BBB (Figure 1B, C). In comparison, control human L-ferritin (LFn) failed to traverse the BBB. The rate of HFn transport across the BBB was between 5 to 6 times higher than that of LFn after one hour of incubation with ferritin proteins (Figure 1B, C). To evaluate whether our HFn nanocarriers are able to transcytose, we also employed a co-culture model consisting of mouse BBB ECs and pericytes. The rate of HFn transport across the co-culture BBB model was similar to the rate observed in the mono culture BBB model (Figure S1A, B). Importantly, we found that HFn nanocarriers maintain their intact structure after traversing the BBB (Figure S1C, D). Together, these results clearly demonstrated that HFn has the ability to traverse the BBB in vitro.

Example: Location Elements



To investigate whether HFn possesses the ability of traversing the BBB, we performed a BBB transcytosis assay both in vitro and in vivo. In a BBB transcytosis assay using in vitro models constructed of either human or mouse BBB ECs (Figure 1A), we found that HFn effectively traversed both the mouse and human BBB (Figure 1B, C). In comparison, control human L-ferritin (LFn) failed to traverse the BBB. The rate of HFn transport across the BBB was between 5 to 6 times higher than that of LFn after one hour of incubation with ferritin proteins (Figure 1B, C). To evaluate whether our HFn nanocarriers are able to transcytose, we also employed a co-culture model consisting of mouse BBB ECs and pericytes. The rate of HFn transport across the co-culture BBB model was similar to the rate observed in the mono culture BBB model (Figure S1A, B). Importantly, we found that HFn nanocarriers maintain their intact structure after traversing the BBB (Figure S1C, D). Together, these results clearly demonstrated that HFn has the ability to traverse the BBB in vitro.

Example: Conclusion



To investigate whether HFn possesses the ability of traversing the BBB, we performed a BBB transcytosis assay both in vitro and in vivo. In a BBB transcytosis assay using in vitro models constructed of either human or mouse BBB ECs (Figure 1A), we found that HFn effectively traversed both the mouse and human BBB (Figure 1B, C). In comparison, control human L-ferritin (LFn) failed to traverse the BBB. The rate of HFn transport across the BBB was between 5 to 6 times higher than that of LFn after one hour of incubation with ferritin proteins (Figure 1B, C). To evaluate whether our HFn nanocarriers are able to transcytose, we also employed a co-culture model consisting of mouse BBB ECs and pericytes. The rate of HFn transport across the co-culture BBB model was similar to the rate observed in the mono culture BBB model (Figure S1A, B). Importantly, we found that HFn nanocarriers maintain their intact structure after traversing the BBB (Figure S1C, D). Together, these results clearly demonstrated that HFn has the ability to traverse the BBB in vitro.

Student Writing

Motivational statements:
In order to show the curative effect, we measured...

To examine curing effect, we performed blood biochemical tests.

In order to avoid more people suffering from falciparum malaria, we performed to use a two-day course of compound dihyroartemisinin to treat it.

In order to show that ARTECOM does have a high cure rate for treating malaria, we carried out ...

In order to identify the effectiveness of Artecom treating the malaria, we selected 50 cases of...

Motivational statements:

To test whether patients were cured, the hematology examination was conducted ...

In order to investigate Artecom 2d 8 tablet therapy have the advantages of high efficiency and quick effect, we carried out Protozoological examination.

Knowing the great curative effect, in order to check the safety of artecom, we used hematological approaches ...

In order to check the influence of artecom on human blood, we measured the hematological situation ...

Motivational statements:

In order to investigate the recurrence situations of 2-days course, we performed this experiment ...

In order to investigate the creatinine variation of patients before and after the treatment. we measured ...
->In order to investigate whether creatinine levels...verb...in patients, we...
In order to investigate the side effect of this treatment, we counted the number of people...

In order to evaluate the toxic side effects of compound dihydroartemisinin for 3 days and 8 tablets, ...

Motivational statements:

In order to evaluate the efficacy of the two-day course of compound dihydroartemisinin for falciparum malaria, we recorded clinical data ...

To estimate the efficacy and effect of the compound dihydroartemisinin, we measured ...

In order to evaluate the treatments of Artecom in falciparum malaria, we measured ...

Location Elements
As shown in Table 1, in order to evaluate ...

The hematology and blood biochemical examination result is shown in Tab.1 ...

...we recorded 28-day follow-up period of the patients as shown in Fig.1.

As is shown in Fig.1, 50 cases were observed.
As shown in Fig 1, there were 50 cases of falciparum malaria.
As shown in Fig 2,there were 34 cases for the index survey .

As table 2 illustrated, during the trail, no obvious Varieties on WBC, RBC were observed , and the concentration of WBC, RBC are Within the normal range.

Location Elements
Our results show that the number of white blood cells and the number of red blood cells have no significant difference before and after the treatment in the examination of 46 patients (Table 3).

AS shown in Figure 2, 89.1% patients were examined less adverse reactions , only 3 cases had headache ...

As show in Fig.1 , using hematological measurement, both the number of white blood cells and red blood cells ...

As shown in Fig.1, the average concentration decrease from 115.5 umol/L to 106.6umol/L ...

Conclusion statements:

These result suggested that artecom have a significant curative effect in falciparum malaria therapy in two-days treatment.

This suggests that a short period to tackle the falciparum malaria and relieve the symptoms is not only feasible but also effective.

These results suggested that this therapy brings no obvious side effects to patients.

Conclusion statements:

These results suggested that Artecome treat Malaria has a high efficiency.

According to the WHO's four-week observation method of chloroquine in clinical sensitivity 1973, these result suggested that the compound dihydroartemisinin has more efficient effect of the treatment than the artemisinin.

In conclusion, the Artecom medicine has both high and rapid curative effect for eliminating falciparum parasites and clearing fever.

Conclusion statements:

Based on the data of blood conditions and the side-effects, this results suggested that Artecom is an effectiveness and safety medicine for us to use.

These results suggested that the treatment programs of oral Artecom 8 pills for 2 days is highly effective.

The result indicates that patients have a better tolerance for ARTECOM to shorten the scheduled treatment time.

Conclusion statements:

Together, these results indicated that artecom didn't have bad influences on human blood.

This result show us that treatment approach have no perceptible negative effect on human blood cells.

That means this treatment cured the patients completely.

In conclusion, Artecom's curative effect is effective.

Conclusion statements:

In conclusion, these results indicated that compound dihydroartemisinin treatment was basically successful.

Basing on all the measurement data,we could prove that this 2-day treatment of Artecom is effective and fast.

In conclusion, these results suggested that ARTECOM has a high cure rate for the treatment of malaria.

In conclusion, recurrence rate was 0 for 46 cases mentioned above.